Table 1 Patient characteristics.

From: Skeletal muscle reprogramming by breast cancer regardless of treatment history or tumor molecular subtype

Patient group

BMI (kg m−2)

BMI change (%)

Body fat (%)

Lean body mass (kg)

Number of days in record

Control

32.7 ± 7.8

−0.16 ± 2.9

37.7 ± 7.5

45.9 ± 6.3

220.1 ± 135.1

All cancer

29.9 ± 7.4

−0.32 ± 5.10

35.5 ± 3.9

46.4 ± 5.6

156.0 ± 242.0

ERPR

28.6 ± 4.5

−0.54 ± 2.9

  

84.20 ± 161.1

HER2

31.1 ± 7.8

1.12 ± 5.9

  

159.9 ± 131.9

TN

29.6 ± 6.5

0.07 ± 6.3

  

313.5 ± 426.6

TP

31.6 ± 11.6

−1.47 ± 6.5

  

125.8 ± 94.99

t Test, two-tailed p (Df, t)

p = 0.18 (69, 1.36)

p = 0.90 (69, 0.13)

p = 0.24 (41, 1.19)

p = 0.82 (41, 0.22)

p = 0.27 (69, 1.12)

ANOVA (Dfbetween, Dfwithin, F)

p = 0.70 (3, 47, 0.47)

p = 0.72 (3, 47, 0.45)

  

p = 0.08* (3, 47, 2.38)

  1. All values are presented as mean ± standard deviation.
  2. t Test: control vs. all cancer.
  3. ANOVA: among patient groups.
  4. Df degrees of freedom, BMI body mass index, ER estrogen receptor, PR progesterone receptor.
  5. *p < 0.10.
Back to article page